Pfizer: PARP-inhibitor combination treatments in prostate cancer

Projects that will be considered for Pfizer support will focus on:

  • Increasing understanding of the rationale for PARPi combinations as potential treatments for prostate cancer
  • Increasing understanding of patient selection/identification for potential treatment with PARPi combinations for prostate cancer
  • Increasing understanding of ongoing clinical trial design exploring PARPi combinations in prostate cancer

Projects focusing on PARPi combinations with androgen receptor targeted therapies are of high interest.

Funding & duration

Projects requesting up to USD $250,000 (approx. AUD $343,500) will be considered.

Submission requirements & due date

Further information

Need help?

This entry was posted in Funding by Award Type, Funding by Faculty, Grants (Project Funds), Health & Medical Sciences, International Funding. Bookmark the permalink.

Comments are closed.